Investors & Media

Cyprium Therapeutics, Inc. (“Cyprium”) is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. In March 2017, Cyprium entered into a Cooperative Research and Development Agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (“NICHD”), part of the NIH, to advance the clinical development of CUTX-101 (Copper Histidinate injection) for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to CUTX-101 to Sentynl Therapeutics, Inc. ZYCUBO® (formerly CUTX-101) was U.S. FDA-approved in 2026 to treat patients with Menkes disease. Cyprium and NICHD also have an ongoing worldwide, exclusive license agreement to develop and commercialize adeno-associated virus (AAV)-based gene therapy, called AAV-ATP7A, to deliver working copies of the copper transporter that is defective in patients with Menkes disease, and to be used in combination with CUTX-101; AAV-ATP7A gene therapy is currently in pre-clinical development and has received FDA Orphan Drug Designation.

Cyprium was founded by, and is a majority‐owned subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO) and is based in Miami, FL.

Contact Information:

Cyprium Therapeutics, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, FL 33154
www.cypriumtx.com

Investor Relations:

Cyprium Therapeutics, Inc.
Jaclyn Jaffe, Investor Relations
ir@cypriumtx.com